# B7-H3 in Brain Malignancies: Immunology and Immunotherapy

Source: https://onco.cc/key-papers/paper-b7-h3-glioblastoma-int-j-biol-sci-2023/  
OnCo record `paper-b7-h3-glioblastoma-int-j-biol-sci-2023` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Review on B7-H3 in Glioma & glioblastoma, in International journal of biological sciences (2023), one of the most cited Europe PMC records with B7-H3 in its title.

## Summary

The immune checkpoint B7-H3 (CD276), a member of the B7 family with immunoregulatory properties, has been identified recently as a novel target for immunotherapy for refractory blood cancers and solid malignant tumors. While research on B7-H3 in brain malignancies is limited, there is growing interest in exploring its therapeutic potential in this context. B7-H3 plays a crucial role in regulating the functions of immune cells, cancer-associated fibroblasts, and endothelial cells within the tumor microenvironment, contributing to the creation of a pro-tumorigenic milieu. This microenvironment promotes uncontrolled cancer cell proliferation, enhanced metabolism, increased cancer stemness, and resistance to standard treatments. Blocking B7-H3 and terminating its immunosuppressive function is expected to improve anti-tumor immune responses and, in turn, ameliorate the progression of tumors. Results from preclinical or observative studies and early-phase trials targeting B7-H3 have revealed promising anti-tumor efficacy and acceptable toxicity in glioblastoma (GBM), diffuse intrinsic pontine glioma (DIPG), medulloblastoma, neuroblastoma, craniopharyngioma, atypical teratoid/rhabdoid tumor, and brain metastases. Ongoing clinical trials are now investigating the use of CAR-T cell therapy and antibody-drug conjugate therapy, either alone or in combination with standard treatments or other therapeutic approaches, targeting B7-H3 in refractory or recurrent GBMs, DIPGs, neuroblastomas, medulloblastomas, ependymomas, and metastatic brain tumors. These trials hold promise for providing effective treatment options for these challenging intracranial malignancies in both adult and pediatric populations.

Indexed on Europe PMC as PubMed record 37564196 (DOI 10.7150/ijbs.85813). Its title names B7-H3 and its text names Glioma & glioblastoma; PubMed types it as a review (Research Support, Non-U.S. Gov't, review-article, Review). It was matched automatically to the idea "Focused-ultrasound BBB opening to deliver ADCs and radioligands to glioma" and no figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: International journal of biological sciences
- Year: 2023
- DOI: 10.7150/ijbs.85813
- Authors: Guo X, Chang M, Wang Y, et al.
- What it means: One of the most cited reviews Europe PMC returns for B7-H3 in Glioma & glioblastoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
- Caveats: Matched by B7-H3 in the title and Glioma & glioblastoma in the title or abstract of the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.; A review summarises other studies; the primary reports it cites are the evidence.

## Sources

- Int J Biol Sci 2023: https://doi.org/10.7150/ijbs.85813
- PubMed: https://pubmed.ncbi.nlm.nih.gov/37564196/
- Europe PMC: https://europepmc.org/article/MED/37564196

## Connected records

- ideas: [Focused-ultrasound BBB opening to deliver ADCs and radioligands to glioma](https://onco.cc/ideas/idea-fus-plus-adc-glioma/)

---
JSON: https://onco.cc/api/v1/entities/paper-b7-h3-glioblastoma-int-j-biol-sci-2023.json